Targeting the most common barrier to IVF success

Up to 80% of IVF cycles fail in women in their mid-30s due to poor egg quality.

Lyvanta^TMis a first in class therapeutic that improves egg quality by targeting meiotic aneuploidy to increase the chance of pregnancy in every IVF cycle.

Extending the window of fertility

Before fertilisation, the number of chromosome copies in the egg must be halved. This ensures that the egg only transfers the correct number of chromosome copies to the embryo.

Older eggs frequently experience errors that cause an incorrect number of chromosome copies to be transferred to the embryo - a condition called meiotic aneuploidy.

Meiotic aneuploidy is a major cause of IVF failure, and drastically increases with age, arising in more than 50% eggs from aged 33 and above.

Preventing meiotic aneuploidy can ensure the embryo has the correct number of chromosomes.

Life-changing impact for families and individuals

In the absence of meiotic aneuploidy, a greater number of high-quality embryos are available for transfer, increasing the success rates of IVF.

We have designed and developed a therapy called Lyvanta^TM that can reduce the occurrence of errors within the egg that lead to meiotic aneuploidy. Lyvanta^TM has shown promising results in pre-clinical studies and is now being developed for clinical trials.